Latest news with #DavidDai
Business Insider
18-07-2025
- Business
- Business Insider
ASML Price Target Slashed by Bernstein Over 2026 Growth Fears
Bernstein analyst David Dai has cut the price target for ASML stock (ASML) from $806 to $743, citing concerns about future growth. The revised price target implies 1.5% downside potential from current levels. Dai also maintained his 'Hold' rating on ASML stock. On July 16, ASML exceeded expectations for both sales and net profit in Q2FY25. However, despite strong demand drivers like artificial intelligence (AI), uncertainty over ASML's growth prospects in 2026 overshadowed the positive results, causing the stock to fall 8.3% yesterday. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. ASML is a Dutch semiconductor company that manufactures advanced semiconductor equipment for chipmakers. The company's CEO, Christophe Fouquet, said that its future potential is marred by macroeconomic and geopolitical uncertainty. 'Therefore, while we still prepare for growth in 2026, we cannot confirm it at this stage,' he added. This statement was in stark contrast to what the company said in November 2023, when it described 2026 as a growth year for the business. ASML's Orders Are Not as Strong as They Appear The analyst highlighted that ASML reported strong results for the second quarter, with revenue and margin beating estimates. Additionally, the company reiterated its full-year fiscal 2025 guidance, projecting a 15% net sales growth over last year. However, Dai noted that, upon close inspection, the orders are not as strong as they appear. ASML made a EUR 1.4 billion adjustment to its Q2 order backlog of EUR 33 billion, due to what the company refers to as 'customers' response to export controls.' The Q2 transcript mentions that customers have canceled orders worth EUR 1.4 billion in light of the tariffs. This also suggests that there could be further cancellations, as President Donald Trump has yet to finalize a deal with the European Union and recently threatened to impose 30% tariffs on the bloc. Wall Street Is Confused by ASML's Forecasts Other analysts also remain confused by ASML's forecasts. Cantor Fitzgerald analyst C J Muse called the company's update ' very confusing and overall disappointing,' noting that ASML suddenly shifted its 2026 outlook from 'growth year-over-year' to 'while we still prepare for growth in 2026, we cannot confirm it at this stage.' Muse maintained his Buy rating and EUR 800 price target on ASML stock. Meanwhile, UBS raised its price target on ASML from EUR 610 to EUR 660, while maintaining a 'Hold' rating. The firm noted that although ASML lowered its FY26 forecast, UBS does not yet view this as 'sufficient to act as a clearing event.' Is ASML Stock a Buy, Hold, or Sell? ASML stock currently has a Moderate Buy consensus rating on TipRanks, based on two Buys and five Hold ratings. The average ASML price target of $877.75 implies 16.3% upside potential from current levels. Year-to-date, ASML stock has gained 9.3%. It is important to note that these ratings could change as analysts revise their recommendations in light of the Q2 results.
Business Insider
13-06-2025
- Business
- Business Insider
Telix Pharmaceuticals (TLPPF) Receives a Buy from UBS
UBS analyst David Dai maintained a Buy rating on Telix Pharmaceuticals (TLPPF – Research Report) today and set a price target of A$36.00. The company's shares closed yesterday at $16.62. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Dai is an analyst with an average return of -26.2% and a 33.33% success rate. Dai covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Iovance Biotherapeutics, and Nurix Therapeutics. Telix Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $22.66, implying a 36.38% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a A$35.00 price target.
Yahoo
18-05-2025
- Business
- Yahoo
Why Iovance Biotherapeutics Tumbled by Nearly 6% Today
An analyst changed his recommendation on the company, and not for the better. He cited concerns arising from its latest quarterly earnings report. 10 stocks we like better than Iovance Biotherapeutics › Iovance Biotherapeutics (NASDAQ: IOVA) didn't quite end the stock trading week on a high note. The company's shares were dinged by almost 6% that day, due largely to an analyst's recommendation downgrade. This occurred on a generally positive day for equities, as the S&P 500 index managed to land in the black with a 0.7% rise. Well before market open, UBS pundit David Dai flipped the switch on his Iovance recommendation, changing it to neutral from his previous buy. Compounding that significantly, he drastically lowered his price target to $2 per share from $17. Dai's latest take on the biotech company comes after the analyst -- and the rest of the investing world -- had slightly over a week to digest the company's latest quarterly earnings. According to reports, Dai pointed out in his update that sales of advanced melanoma drug Amtagvi, far and away Iovance's most leading product, were below expectations. This implies a slower ramp-up of its commercialization, which is concerning given the product's importance. He also expressed concern about higher drop-out rates for the drug. To him, this implies flaws in patient selection. While I think Iovance has impressive science behind it and Amtagvi still has significant potential, there are aspects of the company's business that should have investors worried. As Dai wrote, that ramp-up feels rather slow, and the company's notable revenue guidance cut in that earnings report is also cause for concern. I wouldn't be bullish on this stock right now. Before you buy stock in Iovance Biotherapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Iovance Biotherapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $635,275!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $826,385!* Now, it's worth noting Stock Advisor's total average return is 967% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Tumbled by Nearly 6% Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-04-2025
- Business
- Yahoo
Dai: Good Reason Why China's a Global Manufacturing Hub
The Trump administration is beginning investigations into semiconductor and pharmaceutical imports, a move that could lead to more tariffs and the broadening of the US trade war. David Dai, Managing Director & Senior Analyst for Japan Semiconductor at Bernstein spoke to Bloomberg's Horizons Middle East and Africa anchor Joumanna Bercetche on the impending tariffs and its impact on production especially on iPhones.
Bloomberg
15-04-2025
- Business
- Bloomberg
Dai: Good Reason Why China's a Global Manufacturing Hub
The Trump administration is beginning investigations into semiconductor and pharmaceutical imports, a move that could lead to more tariffs and the broadening of the US trade war. David Dai, Managing Director & Senior Analyst for Japan Semiconductor at Bernstein spoke to Bloomberg's Horizons Middle East and Africa anchor Joumanna Bercetche on the impending tariffs and its impact on production especially on iPhones. (Source: Bloomberg)
